Novartis Lp(a) Drug Fails to Reduce Heart Attack and Stroke Risk Despite Lowering Biomarker
Source Summary
A Novartis drug successfully lowered lipoprotein(a), a cardiovascular risk marker, but failed to reduce the incidence of heart attacks or strokes in clinical trials presented at the American Heart Association conference. The disconnect between the biomarker reduction and clinical outcomes raises questions about the company's cardiovascular drug strategy and the validity of using Lp(a) levels as a predictor of patient benefit.
Why it matters
The failure to translate biomarker improvement into clinical benefit challenges the scientific rationale for Lp(a)-targeting therapies and may require Novartis to reassess its cardiovascular drug development strategy.
